But finding new drugs against misfolded targets is challenging.
TREVENTIS™ Corporation is dedicated to treating and preventing protein misfolding diseases. We utilize a proprietary, patent-pending discovery engine – Common Conformational Morphology (CCM) – to identify druggable active sites in misfolded protein targets. CCM combines unique in silico models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets. Our lead program focuses on anti-misfolding small molecules in tauopathy (3R, 4R, familial mutations and mixed) with relevance to Alzheimer’s disease. We have further CCM-driven efforts in oncology and other neurodegenerative diseases that show the wide utility of our technology platform.